Table 2

Anti-HPV 16, 18 or 6/11/16/18 serological responses, stratified by cytological and histological diagnoses (n = 4211)
Anti-HPV 6/11/16/18 Anti-HPV 16 Anti-HPV 18 Anti-HPV 6 Anti-HPV 11
Histology n % ORa (95% CI) % ORa (95% CI) % ORa (95% CI) % ORa (95% CI) % ORa (95% CI)
Normal 4028 14.7 1.0 5.4 1.0 2.1 1.0 7.7 1.0 3.0 1.0
CIN1 114 28.1 1.2 (0.7-1.9) 14.0 1.3 (0.7-2.4) 0.9 0.2 (0.03-1.9) 12.3 0.9 (0.5-1.7) 7.0 1.8 (0.8-4.0)
CIN2 27 74.1 7.8 (3.2-19.1) 44.4 6.2 (2.7-14.1) 11.1 3.1 (0.8-11.3) 29.6 2.5 (1.0-6.0) 11.1 2.4 (0.7-8.8)
≥CIN3 42 52.4 2.7 (1.4-5.2) 47.6 6.7 (3.4-13.2) 0.0 n/a 4.8 0.3 (0.1-1.2) 4.8 0.9 (0.2-3.8)

aOR: adjusted for age, geographic site and HPV DNA positivity.

Ji et al.

Ji et al. BMC Infectious Diseases 2012 12:137   doi:10.1186/1471-2334-12-137

Open Data